Julian Hanak
Amministratore Delegato presso Purespring Therapeutics Ltd.
Profilo
Julian Hanak is currently the Chief Executive Officer at Purespring Therapeutics Ltd.
He previously worked as a Director at NightstaRx Ltd.
from 2017 to 2019.
He also served as a Member-Supervisory Board at Novasep Holding SAS.
Posizioni attive di Julian Hanak
Società | Posizione | Inizio |
---|---|---|
Purespring Therapeutics Ltd.
Purespring Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Purespring Therapeutics Ltd. provides biotechnological research and experimental development services. The company was founded on April 1, 2020 and is headquartered in London, the United Kingdom. | Amministratore Delegato | 01/01/2023 |
Precedenti posizioni note di Julian Hanak
Società | Posizione | Fine |
---|---|---|
NightstaRx Ltd.
NightstaRx Ltd. Medical/Nursing ServicesHealth Services NightstaRx Ltd. develops and commercializes therapies for retinal dystrophies. It offers retinal gene therapy that provides one-time cure for choroideremia (a rare inherited cause of blindness) and other retinal dystrophies. The company was founded by Robert MacLaren, Miguel Seabra, and Matthew During in January 2014 and is headquartered in London, the United Kingdom. | Direttore/Membro del Consiglio | 07/06/2019 |
Novasep Holding SAS
Novasep Holding SAS Chemicals: Major DiversifiedProcess Industries Novasep Holding SAS provides manufacturing solutions for the life science industries. Its products include agrochemicals fine chemicals and food ingredients. The company was founded by Roger-Marc Nicoud in 1995 and is headquartered in Lyon, France. | Direttore/Membro del Consiglio | - |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 3 |
---|---|
NightstaRx Ltd.
NightstaRx Ltd. Medical/Nursing ServicesHealth Services NightstaRx Ltd. develops and commercializes therapies for retinal dystrophies. It offers retinal gene therapy that provides one-time cure for choroideremia (a rare inherited cause of blindness) and other retinal dystrophies. The company was founded by Robert MacLaren, Miguel Seabra, and Matthew During in January 2014 and is headquartered in London, the United Kingdom. | Health Services |
Purespring Therapeutics Ltd.
Purespring Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Purespring Therapeutics Ltd. provides biotechnological research and experimental development services. The company was founded on April 1, 2020 and is headquartered in London, the United Kingdom. | Commercial Services |
Novasep Holding SAS
Novasep Holding SAS Chemicals: Major DiversifiedProcess Industries Novasep Holding SAS provides manufacturing solutions for the life science industries. Its products include agrochemicals fine chemicals and food ingredients. The company was founded by Roger-Marc Nicoud in 1995 and is headquartered in Lyon, France. | Process Industries |
- Borsa valori
- Insiders
- Julian Hanak